SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (2312)2/19/2018 3:30:55 PM
From: Miljenko Zuanic  Respond to of 3559
 
I do not know. IF it is signed as "completed", at least all data collection are completed and forwarded for analysis (which should took 2-3 weeks). I do think they did have data (at least primary analysis) at CC. Sanofi and REGN indicated that marketing expense related to Praluent promotion will accelerate in 2018, so they "expected" positive results.

Maybe they want maximum impact at Conference, to break Repatha dominance. Still that does not add to good SH-relation and conducts.



To: Felix B who wrote (2312)2/19/2018 3:41:36 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 3559
 
I don't see any factual discrepancy. "Completion" in a clinicaltrials.gov listing means means the completion of patient dosing and patient observation. Unblinding the data is a separate step that happens after completion.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News